<p>Non-Cystic Fibrosis Bronchiectasis (NCFB) is a chronic respiratory condition characterized by permanent dilation of the bronchi, leading to frequent infections, inflammation, and a decline in lung function. It can be caused by various factors, including infections, autoimmune diseases, or it may be idiopathic.</p>
<h2><strong>NCFB Epidemiological Segmentation</strong></h2>
<p>The Epidemiological Segmentation of Non-Cystic Fibrosis Bronchiectasis (NCFB) includes:</p>
<ul>
<li>Total Diagnosed Prevalent Cases of NCFB</li>
<li>Severity-specific Diagnosed Prevalent Cases</li>
<li>Gender-specific Diagnosed Prevalent Cases</li>
<li>Etiology-specific Diagnosed Prevalent Cases</li>
<li>Microbiology of NCFB Patients</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-epidemiology-forecast"><span style="text-decoration: underline;"><strong>NCFB Epidemiology</strong></span></a></h2>
<ul>
<li>The total diagnosed prevalent cases of NCFB in the 7MM were approximately 1,028,651 in 2023. This number is expected to increase during the forecast period (2024-2034), driven by increased awareness, improved screening, and advancements in diagnostic techniques.</li>
<li>In 2023, the United States accounted for the highest number of diagnosed prevalent cases of NCFB, with approximately 380,711 cases.</li>
<li>France had the least diagnosed prevalent cases, with only 37,576 cases.</li>
<li>Among EU4 and the UK, the UK accounted for the highest number of diagnosed prevalent cases, with approximately 224,976 cases in 2023, followed by Spain (149,236 cases) and Italy (89,584 cases).</li>
<li>The severity-specific diagnosed prevalent cases in EU4 and the UK in 2023 were divided as follows:</li>
<li style="list-style-type: none;">
<ul style="list-style-type: circle;">
<li>Moderate cases: ~235,481</li>
<li>Severe cases: ~163,649</li>
<li>Mild cases: ~152,230</li>
</ul>
</li>
<li>Among the gender-specific cases of NCFB in the UK in 2023:
<ul style="list-style-type: circle;">
<li>Female cases: ~130,486</li>
<li>Male cases: ~94,490</li>
</ul>
</li>
<li>In Japan, the majority of etiology-specific diagnosed prevalent cases in 2023 were attributed to unknown or idiopathic causes, accounting for approximately 32,837 cases.</li>
<li>Japan had around 96,580 diagnosed prevalent cases of NCFB in 2023.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-market"><span style="text-decoration: underline;"><strong>NCFB Market</strong></span></a></h2>
<p>The total Non-Cystic Fibrosis Bronchiectasis Treatment Market Size in the 7MM was approximately USD 1.4 billion in 2023.</p>
<h2>NCFB Market Drivers</h2>
<ul>
<li>Increased awareness and improved diagnostic techniques are expected to drive market growth.</li>
<li>The rising number of cases, coupled with advancements in treatment, will further fuel the market.</li>
</ul>
<h2>NCFB Market Barriers</h2>
<ul>
<li>The fragmented nature of the disease&rsquo;s causes makes it difficult to develop universal treatment protocols.</li>
<li>Limited access to specialized care and advanced treatment options in certain regions may hinder market growth.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight"><span style="text-decoration: underline;"><strong>Emerging Therapies for NCFB</strong></span></a></h2>
<ul>
<li>Brensocatib</li>
<li>Inhaled Colistimethate Sodium (CMS I-neb)</li>
<li>FASENRA (benralizumab)</li>
<li>ARINA-1 (RVN-301)</li>
<li>HSK31858</li>
<li>AP-PA02</li>
<li>Ensifentrine (Nebulizer)</li>
<li>Itepekimab</li>
<li>BI 1291583</li>
<li>CHF 6333</li>
<li>CSL787</li>
</ul>
<p>And others</p>
<h2><strong>Key Players in NCFB Market</strong></h2>
<ul>
<li>Insmed</li>
<li>AstraZeneca</li>
<li>Zambon</li>
<li>Renovion</li>
<li>Haisco Pharmaceutical Group</li>
<li>Chiesi Farmaceutici S.p.A</li>
<li>Armata Pharmaceuticals</li>
<li>Verona Pharma</li>
<li>Sanofi</li>
<li>Regeneron Pharmaceuticals</li>
<li>Boehringer Ingelheim</li>
<li>CSL</li>
</ul>
<p>And others</p>

Non-cystic Fibrosis Bronchiectasis Market

Non-cystic Fibrosis Bronchiectasis Market Infographics

Non-cystic Fibrosis Bronchiectasis Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape